Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: A cationic tubular excretion agent

European Journal of Nuclear Medicine

Volumn 25, Issue 12, 1998, Pages 1630-1636

  Sönmezoglu, Kerim ^b   Erdil, T Yusuf ^c   Demir, Mustafa ^c   Sayman, Haluk B ^c   Kabasakal, Levent ^c   Yardi, O Fehmi ^c   Özkara, Hamdi ^c   Mat, M Cem ^c   Solanki, Kishor ^a   Britton, Keith E ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE

Author keywords

Chromium 51 ethylene diamine tetra acetic acid; Cyclosporine nephrotoxicity; Glomerular filtration rate; Plasma clearance rate; Technetium 99m diaminocyclohexane

Indexed keywords

CREATININE; CYCLOSPORIN A; EDETATE CHROMIUM CR 51; TECHNETIUM 99M;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY TUBULE FUNCTION; MALE; NEPHROTOXICITY; PLASMA CLEARANCE; PSORIASIS; TIME; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; CATIONS; CHROMIUM RADIOISOTOPES; CYCLOHEXYLAMINES; CYCLOSPORINE; EDETIC ACID; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RADIOISOTOPE RENOGRAPHY; RADIOPHARMACEUTICALS;

EID: 0032445098     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050341     Document Type: Article

References (26)

1. Tugwell P, Bombardier C, Gent M, Bennett K, Ludwin D, Grace E. Low-dose cyclosporine in rheumatoid arthritis: a pilot study in 52 patients. J Rheumatol 1987; 14: 1108-1114.
2. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind placebo controlled study in 52 patients. Ann Rheum Dis 1988; 47: 127.
3. Deray G, Benhmida M, Hoang PL, Maksud P, Aupetit B, Baumelou A, Jacobs C. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992; 117: 578-583.
4. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 1986; 314: 1219-1225.
5. Dieterle A, Abeywickrama K, von Graffenried B. Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporine. Transplant Proc 1988; 20: 349-355.
6. Mihatsch MJ, Bach JF, Coovadia HM, et al. Cyclosporin-associated nephropathy in patients with autoimmune diseases. Klin Wochenschr. 1988; 66: 43-47.
7. Bennet WM. Renal effects of cyclosporine. J Am Acad Dermatol 1990; 23: 1280-1287.
8. Whiting PH. Mechanism underlying cyclosporine-A nephrotoxicity. Toxicol Lett 1990; 53: 69-73.
9. Akagi, H. Reynolds A, Hjelm M. Cyclosporine-A and its metabolites, distribution in blood and tissues. J Int Med Res 1991; 19: 1-18.
10. Hoitsma AJ, Wetzels JF, Koene RA. Drug induced nephrotoxicity: Aetiology, clinical features and management. Drug Saf 1991; 6: 131-147.
11. Edwards BD, Daley-Yates TP, Maiza A, Testa HJ, Lawson RS, Driscol JO, Chalmers RJ, Ballardie FW. Cyclosporine nephrotoxicity: haemodynamics, tubular dysfunction and abrogation in normal human kidney. Nucl Med Commun 1991; 12: 300.
12. Solanki KK, Theobald AE, Britton KE. Potential new renal imaging agent using the active tubular cationic mechanism. J Nucl Med 1991; 32: 1102.
13. 99mTc-labeled cationic complexes - a new class of renal imaging agents - results of a preliminary study. J Nucl Med 1991; 32: 1105.
14. 99mTc-diaminocyclohexane, a renal tubular agent with cationic transport: results in healthy human volunteers. Nephron 1993; 65: 294-298.
15. Sapirstein LA, Vidt DG, Mandel MJ, Hanusek G. Volumes of distribution and clearances of intravenously injected creatinine in the dog. Am J Physiol 1995; 181: 330-336.
16. 99mTc-with cyclam: concise communication. J Nucl Med 1980; 21: 443-448.
17. Deutsch E. Inorganic radiopharmaceuticals. In: Radiopharmaceuticals: II. New York: Society of Nuclear Medicine; 1979: 129.
18. Herzog KM, Deutsch E, Deutsch K, Silberstein EB, Sarangarajan R, Cacini W. Synthesis and renal excretion of technetium-99m-labeled organic cations. J Nucl Med 1992; 33: 2190-2195.
19. Taylor A, Eshima D, Fritzberg AR, Christian PE, Kasina S. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med 1986; 27: 795-803.
20. Jafri RA, Britton KE, Nimmon CC, et al. Technetium-99m MAG3, a comparison with iodine-123 and iodine-131 orthoiodohippurate, in patients with renal disorders. J Nucl Med 1988; 29: 147-158.
21. Muller-Suur R, Bois-Svenson I, Mesko L. A comparative study of renal scintigraphy and clearance with technetium-99m-MAG3 and I-123-hippurate in patients with renal disorders. J Nucl Med 1990; 31: 1811-1817.
22. Van Nerom CG, Bormans GM, DeRoo MJ, Verbruggen AM. First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 1993; 20: 738-746.
23. Powles AV, Carmichael D, Hulme B, et al. Renal function after long-term low-dose cyclosporin for psoriasis. Br J Dermatol 1990; 122: 665-669.
24. Peters AM, Heckmatt, Hasson N, et al. Renal haemodynamics of cyclosporin A nephrotoxicity in children with juvenile dermatomyositis. Clin Sci 1991; 81: 153-159.
25. 99mTc-diaminocyclohexane (DACH). J Nucl Med 1995; 36: 233P.
26. 99mTc-diaminocyclohexane (DACH), a renal tubular agent with cationic transport excretion, in renal transplant (RTX) patients. Eur J Nucl Med 1995; 22: 835.